Markets.com Logo

CYDY

$--
--%
1d
1w
1m

Analysis and statistics

  • Open
    0.3125$
  • Previous Close
    0.2978$
  • 52 Week Change
    0.39$
  • Day Range
    0.01$
  • 52 Week High/Low
    0.1$ - 0.49$
  • Dividend Per Share
    --
  • Market cap
    372 M$
  • EPS
    -0.01
  • Beta
    1.239
  • Volume
    --

About

CYDY.US represents the common stock of CytoDyn Inc. traded on the over-the-counter (OTC) market in the United States. CytoDyn is a biotechnology company focused on the clinical development and commercialization of leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor. The company has explored leronlimab's potential in various indications, including HIV, COVID-19, and cancer. It's important to note that the company has faced challenges, including regulatory hurdles, clinical trial results that have not always met expectations, and questions surrounding its financial stability. Investors should conduct thorough due diligence and be aware of the risks associated with investing in OTC stocks, particularly those in the biotechnology sector with limited revenues and ongoing clinical development programs.

US May CPI Report: A Key Inflation Gauge and Interest Rate Implications

Ava Grace|--

Trump and Netanyahu's Strained Alliance: Open Disagreements Amidst Political Pressures

Emma Rose|--

Iran's Strategic Pivot: From Proxy Warfare to Direct Confrontation with Israel

Emma Rose|--

Trump's Diminishing Power and Health Scrutiny Ahead of Midterms

Liam James|--

Oracle Q4 Earnings Preview: AI Momentum and Cloud Infrastructure Under Scrutiny

Liam James|--

Japanese Monetary Policy Outlook: Interest Rate Hike on the Horizon Amidst Inflationary Pressures

Emma Rose|--

SpaceX IPO Fuels Capital Rotation: Impact on US Stocks and Future Outlook

Emma Rose|--

Factors

Clinical Trial Results: Positive data from trials of leronlimab, CYDY's main drug, typically boosts the stock price, while negative data leads to declines.

Regulatory Approvals: FDA approval of leronlimab for any indication would likely cause a significant surge in the stock price.

Financial Performance: CYDY's cash position, debt levels, and ability to secure funding impact investor confidence and the stock price.

Market Sentiment: Overall market conditions, investor risk appetite, and sector-specific trends (e.g., biotechnology) can influence CYDY's stock.

Competition: The presence of competing drugs or therapies for the same indications as leronlimab can negatively impact the stock.

Partnerships and Collaborations: Announcements of partnerships with other pharmaceutical companies or research institutions often positively affect the stock.

News and Media Coverage: Positive or negative news articles, social media discussions, and analyst ratings can influence investor sentiment and trading activity.

Management Changes: Changes in the company's leadership or board of directors can sometimes impact investor confidence and stock performance.

Intellectual Property: The strength and validity of CYDY's patents related to leronlimab are crucial for its long-term value and stock price.

Manufacturing and Supply Chain: Any disruptions in the manufacturing or supply chain of leronlimab could negatively impact the stock price.

People Also Watch

Latest news

Bank of Canada Holds Rates Steady at 2.25%: Navigating the Economic Tightrope

Liam James|--

US Inflation Data for May: CPI Rises 0.5%, Driven by Energy Costs

Sophia Claire|--

US CPI Outlook: Inflation Fears Rise Amid Energy Shocks and Policy Uncertainty

Emma Rose|--

Latest Education Articles

What Is the Consumer Price Index? CPI Meaning and Forex Trading Impact

What Is the Consumer Price Index? CPI Meaning and Forex Trading Impact

Julian Parker|--
What Are Government Bonds? A Beginner’s Guide to How They Work

What Are Government Bonds? A Beginner’s Guide to How They Work

Julian Parker|--
Money Management Strategies in Trading

Money Management Strategies in Trading

Julian Parker|--
Recommended Topics